前往化源商城

Clinical calcium 2011-10-01

[Clinical strategies for prevention of drug-induced urinary calculi].

Yasuo Kohjimoto, Yumiko Sasaki, Isao Hara

文献索引:Clin. Calcium 21(10) , 1457-63, (2011)

全文:HTML全文

摘要

Drug-induced urinary calculi, although they account for only 1-2% of urinary calculi, deserve consideration because most of them are preventable. In the drug-containing calculi resulting from the crystallization of a certain drug and its metabolites in the urine, stone analysis can identify the responsible drug. While, in the drug-induced metabolic calculi caused by interference with calcium, oxalate and purine metabolism, careful clinical inquiry is necessary to reveal involvement of a certain drug in stone formation. Better awareness of the possible drugs with lithogenic potential and close surveillance of patients on long-term treatment with these drugs are necessary. Especially, in patients with a history of urolithiaisis, prescription of lithogenic drugs deserve careful consideration.

相关化合物

结构式 名称/CAS号 全部文献
氟罗里硅土 结构式 氟罗里硅土
CAS:1343-88-0
苯溴马隆 结构式 苯溴马隆
CAS:3562-84-3
氨苯蝶啶 结构式 氨苯蝶啶
CAS:396-01-0